Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the Genedata Expressionist® Refiner Genome module, a first-in-class data processing and analysis application for next-generation sequencing and genomic profiling. Featuring a flexible genomic browser capable of visualizing terabytes of data, the solution addresses whole genome analysis including transcriptome, DNA methylome, gene regulation, copy number variations, and Single Nucleotide Polymorphism (SNP). The Genomic Analysis Laboratory at the Salk Institute is providing feedback on the Expressionist Refiner Genome module focusing specifically on whole genome analysis including DNA methylation. Genedata Expressionist will be demonstrated at NGX: Evolution of Next-Generation Sequencing Conference (Rhode Island Convention Center; Booth 7; Sept. 27 – 29).
“Our lab conducts a variety of analyses spanning DNA methylation, RNA sequencing, and chip sequencing,” said Dr. Joseph Ecker, head of the Genomic Analysis Laboratory at the Salk Institute for Biological Studies. “Genedata Expressionist brings together all these data types on a single platform that includes intuitive visualization capabilities. Its visualization and workflows will enable many people within our community - from biologists to bioinformaticists and computational biologists - to use experimental data in their research and collaborations. While we have in-house tools, not everyone understands how to use them. So, it’s imperative to have software tools like Genedata Expressionist that everyone can use, and which align with sequencing power that is developing at a pace faster than Moore’s law.”
A Unified System for Multiple, High Throughput Genomic Profiling Technologies
As next-generation sequencing and other analytical technologies advance the understanding of biological systems and diseases, data volume grows exponentially. Genedata Expressionist Refiner Genome is a unified system that bridges the gap between data generation and the ability to process, analyze and visualize massive amounts of genomic data. Genedata Expressionist is vendor- and technology-independent, maximizing the value of high throughput genomics experiments in combinations such as (but not exclusive to):
An enterprise solution built on client-server architecture, Genedata Expressionist integrates with existing IT infrastructures. Its proven workflow system for automation of recurrent processes provides for improved communication and knowledge sharing while increasing productivity. Additionally, Genedata Expressionist’s audit trails and reporting capabilities ensure data integrity and facilitate FDA submissions.
“With Genedata Expressionist Refiner Genome, scientists for the first time have a single system that gives them an easy way to analyze the vast and rich array of genomic data produced by next-generation sequencing technologies,” said Dr. Othmar Pfannes, CEO of Genedata. “We could not, however, deliver this solution without the support of industry pioneers such as the Genomic Analysis Laboratory, which is at the forefront of molecular biology research. Collaborating with leading researchers helps us to better understand data types, and the ways in which scientists want to use that data, empowering Genedata to continually develop innovative solutions rooted in real-world experience.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.